16 completed. 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
Follow Anesthesia, General: new trials by email Literature Review of Anesthesia, General trials Research Report on Anesthesia, General
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influence of Sevoflurane and Propofol on Maximum Muscular Strength, Speed of Contraction and Relaxation Sevoflurane, Propofol - Anesthesia, General, Neuromuscular Transmission Disorders | Phase 3 | Completed | Brugmann University Hospital | 48 | 2023-01-20 | 2023-07-10 |
| The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics Sevoflurane, Desflurane - Anesthesia, General | Phase 3 | Completed | Kangbuk Samsung Hospital | 90 | 2016-02-16 | 2018-05-08 |
| Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System Closed-Loop propofol and remifentanil system by Bispectral Index, Open-Loop propofol and remifentanil by Target Controlled Infusion, propofol - Anesthesia, General, Anesthesia, Intravenous | Phase 3 | Completed | Universidad de Antioquia | 150 | 2015-06-01 | 2016-06-20 |
| Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED) Sugammadex - Anesthesia, General, Neuromuscular Blockade | Phase 3 | Completed | Merck Sharp & Dohme LLC | 164 | 2010-01-01 | 2015-10-07 |
| Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED) Sugammadex, neostigmine - Anesthesia, General, Neuromuscular Blockade | Phase 3 | Completed | Merck Sharp & Dohme LLC | 308 | 2010-01-01 | 2015-11-02 |
| Influence of Muscle Relaxation on a Closed-loop Anesthesia System muscle relaxant, normal saline - Anesthesia, General | Phase 3 | Completed | Hopital Foch | 140 | 2009-12-01 | 2016-09-23 |
| Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699) Rocuronium, Sugammadex, Neostigmine - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 140 | 2008-07-16 | 2017-05-16 |
| Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) Sugammadex, Rocuronium, Sevoflurane - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 52 | 2006-12-07 | 2019-11-25 |
| Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026) Sugammadex, Succinylcholine, Rocuronium - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 115 | 2006-02-10 | 2019-04-11 |
| Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029) Sugammadex, Rocurium - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 162 | 2005-12-29 | 2019-04-02 |
| Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) sugammadex, neostigmine, vecuronium - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 182 | 2005-11-28 | 2019-03-19 |
| Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) Sugammadex, Neostigmine - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 198 | 2005-11-17 | 2019-03-04 |
| Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931) Sugammadex, neostigmine - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 84 | 2005-11-10 | 2019-11-15 |
| Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Sugammadex, Rocuronium - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 86 | 2005-10-27 | 2019-04-12 |
| Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) Sugammadex, Rocuronium - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 224 | 2005-10-27 | 2019-03-27 |
| Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED) Sugammadex - Anesthesia, General | Phase 3 | Completed | Merck Sharp & Dohme LLC | 30 | 2005-06-01 | 2017-06-16 |
Neuromuscular Junction Diseases (1)
Nervous System Diseases (1) · Neuromuscular Diseases (1)
Sugammadex (12) · Rocuronium (6) · Neostigmine (5) · Glycopyrrolate (3) · Propofol (3) · Sevoflurane (3) · Atropine (2) · Desflurane (1) · Saline Solution (1) · Succinylcholine (1) · Vecuronium Bromide (1)
Merck Sharp & Dohme LLC (12) · Brugmann University Hospital (1) · Hopital Foch (1) · Kangbuk Samsung Hospital (1) · Universidad de Antioquia (1)
Belgium (1) · Colombia (1) · France (1) · South Korea (1)
Fabian Casas, MD, Ms (1) · Kyoungho Ryu, M.D. (1) · Marc Fischler, MD (1)
PMID 10981581, PMID 11465585, PMID 16672092, PMID 17591128, PMID 18385265, PMID 18806028, PMID 18946293, PMID 19387176, PMID 19512873, PMID 19713265, PMID 20007792, PMID 20683334, PMID 20809967, PMID 21239968, PMID 21950720, PMID 22608583, PMID 22698066, PMID 23015618, PMID 23427212, PMID 25157214, PMID 25187755